SEC Form 10-Q filed by Tectonic Therapeutic Inc.
$TECX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/22/2024 | $55.00 | Overweight | Wells Fargo |
| 6/26/2024 | Overweight | Piper Sandler | |
| 6/24/2024 | Buy | TD Cowen |
Wells Fargo initiated coverage of Tectonic Therapeutic with a rating of Overweight and set a new price target of $55.00
Piper Sandler initiated coverage of Tectonic Therapeutic with a rating of Overweight
TD Cowen initiated coverage of Tectonic Therapeutic with a rating of Buy
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
10-Q - Tectonic Therapeutic, Inc. (0001681087) (Filer)
8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)
Leerink Partners analyst David Risinger initiates coverage on Tectonic Therapeutic (NASDAQ:TECX) with a Outperform rating and announces Price Target of $49.
13D
SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)
SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)
SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)
Phase 1a results support further development of TX000045 ("TX45") for Group 2 Pulmonary Hypertension in HFpEF ("PH-HFpEF"), based on favorable pharmacokinetic profile and impact on renal plasma flow ("RPF")TX45 showed a favorable safety profile, with no observed injection site reactions, immunogenicity, or detection of anti-drug antibodiesRPF-based exposure-response model enabled APEX Phase 2 dose selectionUpcoming topline results from the ongoing TX45 clinical program includes Phase 1b hemodynamic, proof-of-concept trial data expected in late 1Q or early 2Q'2025, and APEX Phase 2 clinical trial data expected in 2026 WATERTOWN, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeut
Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotechnology compan
WATERTOWN, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs"), today announced that it will present a poster at AHA 2024 highlighting Phase 1a data for its lead asset TX000045 ("TX45"), a long-acting, relaxin. TX45 is being developed as a potential best-in-class therapy for patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction ("PH-HFpEF"). Tectonic announced topline results from the study on September 19, 2024. AHA 2024 P
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)
Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotechnology compan
TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech